UBS Maintains Neutral on Qiagen, Lowers Price Target to $47

Benzinga Newsdesk www.benzinga.com Negative 79.8%

Neg 79.8% Neu 0% Pos 0%

UBS analyst Dan Leonard maintains Qiagen (NYSE:QGEN) with a Neutral and lowers the price target from $52 to $47.

Comments

No comments yet. Be the first!